TIGIT and cancer: Because CD155 can bind to CD226, a receptor expressed on T cells and NKs, and result in the stimulation of T cells and NKs, TIGIT competes with CD155, leading to an overall immunosuppressive phenotype and poor overall survival in cancer patients [103].